Finch is rapidly deploying its Human-First Discovery platform to a broad range of diseases linked to dysbiosis of the gut microbiome. We are systematically exploring the most promising diseases by generating and analyzing interventional data to empirically determine whether microbial interventions have a meaningful clinical impact. We are deploying our machine learning platform against these datasets to evaluate whether a Rationally-Selected Microbiota therapy is likely to be efficacious, or whether a Full-Spectrum Microbiota therapy is more promising. Finch currently is involved in 36 clinical trials aimed at addressing important unmet medical needs.